Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use

导出原文传递

翻译打印收藏纠错

作者： Lorente, D. ^[1] ; Mateo, J. ^[2] ; Templeton, A. J. ^[3] ; Zafeiriou, Z. ^[4] ; Bianchini, D. ^[5] ; Ferraldeschi, R. ; Bahl, A. ; Shen, L. ; Su, Z. ; Sartor, O. ; de Bono, J. S.

作者单位： Bristol Haematol & Oncol Ctr, Dept Clin Oncol, Bristol, Avon, England ^[1] Sanofi Oncol, Oncol, Cambridge, MA USA ^[2] Kantonsspital, Dept Med Oncol, St Gallen, Switzerland ^[3] Tulane Univ, Dept Med, Sect Hematol & Med Oncol, New Orleans, LA 70118 USA ^[4] Royal Marsden NHS Fdn Trust, Prostate Canc Targeted Therapy Grp, Sutton SM2 5PT, Surrey, England ^[5]

关键词 neutrophil-lymphocyte ratio castration-resistant prostate cancer cabazitaxel steroids prognostic biomarker treatment response

发布时间 2015-06-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交